Share-based Payment Arrangement, Expense of Minerva Neurosciences, Inc. from 31 Mar 2014 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Minerva Neurosciences, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2014 to 30 Sep 2025.
  • Minerva Neurosciences, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $272,897, a 11% decline year-over-year.
  • Minerva Neurosciences, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $1,117,994, a 34% decline year-over-year.
  • Minerva Neurosciences, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $1,325,525, a 33% decline from 2023.
  • Minerva Neurosciences, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1,968,381, a 52% decline from 2022.
  • Minerva Neurosciences, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $4,108,819, a 21% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Minerva Neurosciences, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $1,117,994 $272,897 -$34,811 -11% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $1,152,805 $298,218 -$31,100 -9.4% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $1,183,905 $297,229 -$141,620 -32% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $1,325,525 $249,650 -$361,414 -59% 01 Oct 2024 31 Dec 2024 10-K 25 Feb 2025 2024 FY
Q3 2024 $1,686,939 $307,708 -$64,235 -17% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $1,751,174 $329,318 -$279,597 -46% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $2,030,771 $438,849 +$62,390 +17% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $1,968,381 $611,064 -$336,620 -36% 01 Oct 2023 31 Dec 2023 10-K 25 Feb 2025 2024 FY
Q3 2023 $2,305,001 $371,943 -$664,931 -64% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $2,969,932 $608,915 -$462,690 -43% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $3,432,622 $376,459 -$676,197 -64% 01 Jan 2023 31 Mar 2023 10-Q 01 May 2024 2024 Q1
Q4 2022 $4,108,819 $947,684 -$256,660 -21% 01 Oct 2022 31 Dec 2022 10-K 22 Feb 2024 2023 FY
Q3 2022 $4,365,479 $1,036,874 -$77,652 -7% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $4,443,131 $1,071,605 -$312,455 -23% 01 Apr 2022 30 Jun 2022 10-Q 01 Aug 2023 2023 Q2
Q1 2022 $4,755,586 $1,052,656 -$463,408 -31% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $5,218,994 $1,204,344 -$760,181 -39% 01 Oct 2021 31 Dec 2021 10-K 08 Mar 2023 2022 FY
Q3 2021 $5,979,175 $1,114,526 -$941,509 -46% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $6,920,684 $1,384,060 -$2,101,422 -60% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $9,022,106 $1,516,064 -$682,123 -31% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022 2022 Q1
Q4 2020 $9,704,229 $1,964,525 -$205,460 -9.5% 01 Oct 2020 31 Dec 2020 10-K 01 Mar 2022 2021 FY
Q3 2020 $9,909,689 $2,056,035 -$165,154 -7.4% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021 2021 Q3
Q2 2020 $10,074,843 $3,485,482 +$1,165,090 +50% 01 Apr 2020 30 Jun 2020 10-Q 02 Aug 2021 2021 Q2
Q1 2020 $8,909,753 $2,198,187 -$263,512 -11% 01 Jan 2020 31 Mar 2020 10-Q 12 May 2021 2021 Q1
Q4 2019 $9,173,265 $2,169,985 +$260,897 +14% 01 Oct 2019 31 Dec 2019 10-K 08 Mar 2021 2020 FY
Q3 2019 $8,912,368 $2,221,189 -$40,592 -1.8% 01 Jul 2019 30 Sep 2019 10-Q 02 Nov 2020 2020 Q3
Q2 2019 $8,952,960 $2,320,392 +$422,519 +22% 01 Apr 2019 30 Jun 2019 10-Q 03 Aug 2020 2020 Q2
Q1 2019 $8,530,441 $2,461,699 +$347,763 +16% 01 Jan 2019 31 Mar 2019 10-Q 04 May 2020 2020 Q1
Q4 2018 $8,182,678 $1,909,088 01 Oct 2018 31 Dec 2018 10-K 09 Mar 2020 2019 FY
Q3 2018 $2,261,781 +$1,027,896 +83% 01 Jul 2018 30 Sep 2018 10-Q 04 Nov 2019 2019 Q3
Q2 2018 $1,897,873 01 Apr 2018 30 Jun 2018 10-Q 05 Aug 2019 2019 Q2
Q1 2018 $2,113,936 +$813,936 +63% 01 Jan 2018 31 Mar 2018 10-Q 06 May 2019 2019 Q1
Q3 2017 $1,233,885 01 Jul 2017 30 Sep 2017 10-Q 05 Nov 2018 2018 Q3
Q1 2017 $1,300,000 +$500,000 +62% 01 Jan 2017 31 Mar 2017 10-Q 03 May 2018 2018 Q1
Q1 2016 $800,000 +$500,000 +167% 01 Jan 2016 31 Mar 2016 10-Q 04 May 2017 2017 Q1
Q1 2015 $300,000 $0 0% 01 Jan 2015 31 Mar 2015 10-Q 03 May 2016 2016 Q1
Q3 2014 $300,000 01 Jul 2014 30 Sep 2014 10-Q 06 Nov 2014 2014 Q3
Q1 2014 $300,000 01 Jan 2014 31 Mar 2014 10-Q 07 May 2015 2015 Q1

Minerva Neurosciences, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $1,325,525 -$642,856 -33% 01 Jan 2024 31 Dec 2024 10-K 25 Feb 2025 2024 FY
2023 $1,968,381 -$2,140,438 -52% 01 Jan 2023 31 Dec 2023 10-K 25 Feb 2025 2024 FY
2022 $4,108,819 -$1,110,175 -21% 01 Jan 2022 31 Dec 2022 10-K 22 Feb 2024 2023 FY
2021 $5,218,994 -$4,485,235 -46% 01 Jan 2021 31 Dec 2021 10-K 08 Mar 2023 2022 FY
2020 $9,704,229 +$530,964 +5.8% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2022 2021 FY
2019 $9,173,265 +$990,587 +12% 01 Jan 2019 31 Dec 2019 10-K 08 Mar 2021 2020 FY
2018 $8,182,678 +$3,149,555 +63% 01 Jan 2018 31 Dec 2018 10-K 09 Mar 2020 2019 FY
2017 $5,033,123 +$1,461,912 +41% 01 Jan 2017 31 Dec 2017 10-K 12 Mar 2019 2018 FY
2016 $3,571,211 +$1,368,976 +62% 01 Jan 2016 31 Dec 2016 10-K 12 Mar 2018 2017 FY
2015 $2,202,235 -$15,764,376 -88% 01 Jan 2015 31 Dec 2015 10-K 12 Mar 2018 2017 FY
2014 $17,966,611 01 Jan 2014 31 Dec 2014 10-K 13 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.